Manipulating erythropoiesis in animal models of beta-thalassemia
Assoc. Prof. Stefano Rivella
New York, United States of America
Disclosure : S. Rivella is a consultant for Novartis, Isis and Biomarin Pharmaceuticals. In addition, he is a co-inventor for the patents US8058061 B2 C12N 20111115 and US7541179 B2
C12N 20090602. The consulting work and intellectual property of S. Rivella did not affect in any way the design, conduct, or reporting of this research.
30 slide(s) – 00:21:27 – English – 2012-06-15
Characterization of factors involved in the regulation of normal and abnormal erythropoiesis as well as iron metabolism. Description of new potential therapeutic approaches that have the potential to improve significantly the way patients affected by altered erythropoiesis and iron metabolism are treated.
MANIPULATING ERYTHROPOIESIS IN ANIMAL MODELS OF BETA-THALASSEMIA